8 completed, 3 unknown. 11 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 8, Unknown 3 |
Follow Cryonove Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face CRYONOVE (EC14_4osc), CRYONOVE (EC05osc) - Lentigo, Solar Lentigo | Not applicable | Completed | Cryonove Pharma | 30 | 2024-09-16 | 2024-12-24 |
| Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face CRYONOVE (EC14_4osc), CRYONOVE (EC+05_1osc), CRYONOVE (EC+05_2osc) - Lentigo, Solar Lentigo | Not applicable | Unknown | Cryonove Pharma | 45 | 2024-04-01 | 2024-04-17 |
| Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins prototypes 1 everyday, prototypes 1 every week, prototypes 1 every two weeks - Solar Lentigo, Senile Lentigo | Not applicable | Unknown | Cryonove Pharma | 120 | 2023-09-01 | 2023-06-02 |
| Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) Condition 1 : Prototypes (816-v1) every weeks, Condition 2 : Prototypes (816-v1) every two weeks - Solar Lentigo, Senile Lentigo | Not applicable | Unknown | Cryonove Pharma | 80 | 2023-06-10 | 2023-06-01 |
| Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots. Prototypes (816-v1 001) to (816-v1 050), Prototype (816-v1 051) to (816-v1 100), Prototypes (816-v1 101) to (816-v1 150) - Solar Lentigo, Senile Lentigo | Not applicable | Completed | Cryonove Pharma | 32 | 2023-04-17 | 2024-01-19 |
| Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots Prototypes (816-v1 301) to (816-v1 355) every week, Prototypes (816-v1 301) to (816-v1 355) every two weeks - Lentigo Solar, Senile Lentigo | Not applicable | Completed | Cryonove Pharma | 20 | 2023-04-04 | 2023-11-03 |
| Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots Prototypes (815-v1 001) to (815-v1 050), Prototype (815-v1 051) to (815-v1 100), Prototypes (815-v1 101) to (815-v1 150) - Lentigo Solar | Not applicable | Completed | Cryonove Pharma | 33 | 2022-10-21 | 2023-06-15 |
| Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Post-inflamamatory Hyperpigmentation (PIH). Prototype (814A-v1), Prototype (814B-v1), Prototype (814C-v1) - Post-inflammatory Hyperpigmentation | Not applicable | Completed | Cryonove Pharma | 12 | 2022-10-18 | 2023-06-26 |
| Tolerance of Cyto-selective Difluoroethane-based Cryotherapy Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1) - Solar Lentigo | Not applicable | Completed | Cryonove Pharma | 3 | 2022-01-17 | 2022-08-19 |
| Tolerance and Mode of Administration of Cyto-selective Cryotherapy Treatments in Face Brown Spots: Proof of Concept (810A-v1) device prototype, (810B-v1) device prototype, (810C-v1) device prototype - Solar Lentigo | Not applicable | Completed | Cryonove Pharma | 23 | 2021-12-15 | 2022-08-19 |
| Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots PROOF OF CONCEPT EC16 medical device (CE marked), device prototype (810A-v1), device prototype (810B-v1) - Lentigo Solar | Not applicable | Completed | Cryonove Pharma | 12 | 2021-05-14 | 2022-06-30 |
Hyperpigmentation (9) · Skin Diseases (6) · Lentigo (3) · Melanosis (1) · Pigmentation Disorders (1)
South Africa (4) · Ukraine (3) · Georgia (2) · France (1)
Beverley Summers (1) · Beverley Summers, Pr (1) · Michel Cadot (1) · Natalia Didenko, MD (1)